CO6862153A2 - Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) - Google Patents

Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Info

Publication number
CO6862153A2
CO6862153A2 CO14013113A CO14013113A CO6862153A2 CO 6862153 A2 CO6862153 A2 CO 6862153A2 CO 14013113 A CO14013113 A CO 14013113A CO 14013113 A CO14013113 A CO 14013113A CO 6862153 A2 CO6862153 A2 CO 6862153A2
Authority
CO
Colombia
Prior art keywords
hcv
hepatitis
infections
virus
treatment
Prior art date
Application number
CO14013113A
Other languages
English (en)
Spanish (es)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6862153(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6862153A2 publication Critical patent/CO6862153A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO14013113A 2011-08-19 2014-01-23 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) CO6862153A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
CO6862153A2 true CO6862153A2 (es) 2014-02-10

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14013113A CO6862153A2 (es) 2011-08-19 2014-01-23 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Country Status (38)

Country Link
US (2) US8927593B2 (enExample)
EP (2) EP2744332B1 (enExample)
JP (2) JP6367712B2 (enExample)
KR (1) KR101913800B1 (enExample)
CN (1) CN103732065B (enExample)
AR (1) AR087563A1 (enExample)
AU (1) AU2012299295B2 (enExample)
BR (1) BR112014002845A2 (enExample)
CA (1) CA2844086A1 (enExample)
CL (2) CL2014000393A1 (enExample)
CO (1) CO6862153A2 (enExample)
CR (1) CR20140078A (enExample)
CY (1) CY1118399T1 (enExample)
DK (1) DK2744332T3 (enExample)
DO (1) DOP2014000034A (enExample)
EA (1) EA032841B1 (enExample)
ES (1) ES2611731T3 (enExample)
HR (1) HRP20161743T1 (enExample)
HU (1) HUE030300T2 (enExample)
IL (1) IL230487B (enExample)
IN (1) IN2014CN00572A (enExample)
JO (1) JO3281B1 (enExample)
LT (1) LT2744332T (enExample)
MA (1) MA35443B1 (enExample)
ME (1) ME02588B (enExample)
MX (1) MX354676B (enExample)
PE (1) PE20141201A1 (enExample)
PH (1) PH12014500385A1 (enExample)
PL (1) PL2744332T3 (enExample)
PT (1) PT2744332T (enExample)
RS (1) RS55462B1 (enExample)
SG (1) SG10201606883QA (enExample)
SI (1) SI2744332T1 (enExample)
SM (2) SMT201700028T1 (enExample)
TW (1) TWI538915B (enExample)
UY (1) UY34274A (enExample)
WO (1) WO2013028371A1 (enExample)
ZA (1) ZA201401020B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735542T3 (es) 2011-08-17 2019-12-19 Glaxosmithkline Llc Procedimientos terapéuticos
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
US10308937B2 (en) * 2014-11-10 2019-06-04 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for Hepatitis C
CA2967195A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
EP3589630B1 (en) * 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
MA51611A (fr) * 2018-01-17 2021-04-21 Glaxosmithkline Ip Dev Ltd Inhibiteurs de pi4kiiibêta
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
ES2571219T3 (es) 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
BR0315937A (pt) * 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
WO2008051244A2 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
DK1988779T5 (en) 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP3150589A1 (en) 2007-06-08 2017-04-05 MannKind Corporation Ire-1a inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
CN101910145A (zh) * 2008-02-14 2010-12-08 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
WO2012067663A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
ES2735542T3 (es) * 2011-08-17 2019-12-19 Glaxosmithkline Llc Procedimientos terapéuticos
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections

Also Published As

Publication number Publication date
EA032841B1 (ru) 2019-07-31
PL2744332T3 (pl) 2017-03-31
BR112014002845A2 (pt) 2017-02-21
TWI538915B (zh) 2016-06-21
CR20140078A (es) 2014-03-20
KR101913800B1 (ko) 2018-11-01
AU2012299295B2 (en) 2016-03-31
US8927593B2 (en) 2015-01-06
JP2017125010A (ja) 2017-07-20
ES2611731T3 (es) 2017-05-10
PE20141201A1 (es) 2014-10-03
IN2014CN00572A (enExample) 2015-04-03
LT2744332T (lt) 2017-01-10
RS55462B1 (sr) 2017-04-28
MA35443B1 (fr) 2014-09-01
CN103732065B (zh) 2016-10-26
CY1118399T1 (el) 2017-06-28
EP2744332B1 (en) 2016-10-26
US20150080343A1 (en) 2015-03-19
JP6367712B2 (ja) 2018-08-01
IL230487B (en) 2019-06-30
IL230487A0 (en) 2014-03-31
SMT201700028T1 (it) 2017-03-08
PH12014500385A1 (en) 2020-06-22
MX2014001989A (es) 2014-02-27
AU2012299295A1 (en) 2014-02-20
EP3199531A1 (en) 2017-08-02
CA2844086A1 (en) 2013-02-28
HUE030300T2 (en) 2017-04-28
EP2744332A1 (en) 2014-06-25
WO2013028371A1 (en) 2013-02-28
DK2744332T3 (en) 2017-01-16
CN103732065A (zh) 2014-04-16
MX354676B (es) 2018-03-15
EP2744332A4 (en) 2015-01-14
TW201321390A (zh) 2013-06-01
CL2014000393A1 (es) 2014-08-01
SG10201606883QA (en) 2016-10-28
JO3281B1 (ar) 2018-09-16
US20130237501A1 (en) 2013-09-12
US9682999B2 (en) 2017-06-20
EA201490213A1 (ru) 2014-07-30
SI2744332T1 (sl) 2017-01-31
PT2744332T (pt) 2017-01-24
HRP20161743T1 (hr) 2017-02-24
DOP2014000034A (es) 2014-06-01
CL2017000293A1 (es) 2017-10-06
AR087563A1 (es) 2014-04-03
SMT201700028B (it) 2017-03-08
ZA201401020B (en) 2020-11-25
ME02588B (me) 2017-06-20
KR20140054287A (ko) 2014-05-08
UY34274A (es) 2013-04-05
JP2014527529A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
CO6862153A2 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
SMT201600325B (it) Alifani, ciclofani, eterafani, eterofani, etero-eterafani e metalloceni sostituiti utili per il trattamento di infezioni da hcv
DK3590928T3 (da) Pyrimidinderivater til behandling af virusinfektioner
CL2015000482A1 (es) Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b
IL232046A0 (en) Purine derivatives for the treatment of viral infections
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
HUE057928T2 (hu) Coronaviridae családba tartozó vírus okozta fertõzések kezelésére szolgáló eljárások
CL2015000925A1 (es) Compuestos derivados de heterociclos nitrogenados; composicion farmaceutica; un metodo para tratar infecciones viricas provocadas por virus sincicial respiratorio (vsr)
UA116087C2 (uk) Композиція для лікування вірусу гепатиту c
ZA201501018B (en) Compounds for the treatment of paramoxyvirus viral infections
DK2958900T3 (da) 2-aminopyrimidinderivater til behandling af virusinfektioner
CO6821947A2 (es) Inhibidores del virus de la hepatitis c
BR112013012998A2 (pt) compostos para tratar infecções por vírus sincicial respiratório
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
CO6821952A2 (es) Inihibidores del virus de la hepatitis c
DK2939665T3 (da) Farmaceutisk sammensætning til behandling af hiv-infektioner
EP2756102A4 (en) DETECTION OF VIRAL INFECTION
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
EP2900656A4 (en) SPIRRING COMPOUNDS AS HEPATITIS C-VIRUS (HCV) INHIBITORS
DK2723336T3 (da) Sammensætninger til behandling af fragilt X-syndrom
CO6801768A2 (es) Procesos para la preparación de inhibidores del virus de la hepatitis
BR112013011405A2 (pt) composição farmacêutica para tratar infecções por hcv
ZA201306342B (en) The treatment of viral infections
BR112013025021A2 (pt) alisporivir para tratar infecções por vírus de hepatite c.

Legal Events

Date Code Title Description
FG Application granted